Coronary Artery Disease: Overview, Risk Factors, Treatments, and Diagnostic Methods

Assignments

  • Very minor assignment due for the class, referred to as the exam wrapper.

  • The exam wrapper is expected to be short and straightforward.

Coronary Artery Disease (CAD)

  • Concerns about plaque in the coronary arteries.

  • Risks of plaque becoming unstable and rupturing.

  • Primary issue located in the arteries.

Arterial vs. Venous Thrombosis

  • Arterial Thrombosis

    • Clots that form in arteries are rich in platelets and form around ruptured plaques.

    • Formed under high shear forces (blood pressure).-

  • Venous Thrombosis

    • Generally occurs with lower pressure, often in veins with less shear force.

    • Occurs over time, resulting in reduced clot formation compared to arteries.

High Shear Forces

  • High shear forces are primarily caused by blood pressure, which is significantly higher in arteries than in veins.

Collateral Circulation

  • Definition: Development of new blood vessels in response to blockages in the arteries (e.g., due to plaque accumulation).

  • Who Develops Collateral Circulation:

    • Older adults.

    • Individuals who are physically fit.

  • New blood vessels do not form quickly; collateral circulation takes a significant amount of time to develop.

Risk Factors for Coronary Artery Disease

  • Nonmodifiable Factors:

    • Age: Cannot be changed.

    • Gender: Not modifiable; higher incidence in middle-aged men and menopausal women.

    • Race: Fixed characteristics.

    • Genetics: Generally nonmodifiable, but can consider partner selection for potential genetic risks.

  • Major Modifiable Factors: These can greatly influence CAD risk, and include:

    • Hyperlipidemia

    • Hypertension

    • Tobacco Use

    • Noted as a significant factor; chronic smokers often exhibit compromised coronary arteries.

    • Physical Inactivity

    • Body Mass Index (BMI)

  • Contributing Modifiable Factors: These factors can increase risk when paired with another modifiable or nonmodifiable risk.

    • Diabetes: Hyperglycemia can also increase the risk of CAD.

    • Metabolic Syndrome: Group of conditions including:

    • Increased glucose levels, high blood pressure, increased waist circumference, low HDL, and high triglycerides.

    • Psychological States: Stress and depression significantly correlate with CAD.

    • Substance Use: E.g., methamphetamines causing increased heart rate and blood pressure, leading to higher risk.

Cholesterol and Plaque Formation

  • Cholesterol: A type of fat crucial for hormone production, synthesized in the liver but can also come from dietary intake.

  • Types of Fats:

    • Saturated Fats

    • Unsaturated Fats

    • Polyunsaturated Fats

  • Cholesterol Levels and Types:

    • LDL and VLDL are considered "bad" cholesterol; high levels are detrimental and promote plaque buildup.

    • HDL is known as "good" cholesterol; functions to remove LDL and VLDL from circulation.

  • Suggested optimal levels:

    • Total cholesterol: Less than 200 mg/dL

    • LDL: Less than 100 mg/dL is optimal.

    • HDL: Higher than 60 mg/dL is preferred.

    • Triglycerides: Less than 150 mg/dL is desired.

Treatment Groups for CAD

  • Patients with existing clinical atherosclerotic cardiovascular disease require medication immediately.

  • Individuals with an LDL level greater than 190 mg/dL also require treatment.

  • Diabetic patients aged 40 and older should be treated if they have high LDL levels or other risk factors.

  • Risk stratification is often calculated to determine medication necessity.

Prevention Strategies for CAD

  • Maintain a healthy weight with weight loss reducing risk.

  • Diet modifications: reduce sodium intake, low cholesterol and saturated fats, high fruits, veggies, and lean meats.

  • Limit alcohol consumption.

  • Collaborate with dietitians for patient education on dietary intervention.

Patient Management

  • Exercise: Involved in lifestyle modifications for reducing CAD risks.

  • Substance Use: Establish limits.

  • Drug Therapy: Medications are necessary for some patients based on risk factors.

Medications for Cholesterol Management

  • Statins:

    • Work by blocking HMG CoA reductase to reduce cholesterol synthesis in the liver.

    • Side effects include myopathy, which can lead to rhabdomyolysis (muscle breakdown).

  • Injectable medications: Newer alternatives improve LDL management but come with limitations like cost and ease of use.

  • Other Drugs:

    • Niacin (Vitamin B3) can cause flushing; less effective in reducing cholesterol.

    • Bile Acid Sequestrants bind cholesterol, but can cause digestive symptoms.

    • Zetia (cholesterol absorption inhibitor) reduces cholesterol absorption during digestion, should not be taken with bile acid sequestrants.

    • Fibric Acid Derivatives can contribute to gallstone formation.

Angina

  • Definition: Angina refers to cardiac-related chest pains, indicative of coronary artery issues.

  • Types of Angina:

    • Chronic Stable Angina: Predictable chest pain that occurs during exertion and resolves with rest.

    • Silent Angina: Presents without classic symptoms, especially in diabetic patients, may show nonspecific symptoms.

    • Prinzmetal's Angina: Caused by coronary artery spasms resulting in temporary chest pain, potentially associated with conditions like migraines.

    • Microvascular Angina: Occurs without significant plaque in major arteries, commonly seen in postmenopausal women; may require advanced imaging to identify.

Diagnostic Methods for CAD

  • Stress Testing: Evaluates heart function under exertion; includes treadmill tests or pharmacological stress tests with imaging.

  • Echocardiograms: Assesses heart muscle function; looks for wall motion abnormalities and estimates ejection fraction.

  • Angiography: Invasive method involving catheterization to visualize coronary arteries using contrast; weighed against patient risks, such as allergies or renal function.

Risk Evaluation

  • Different tools and scoring systems estimate patient risk for atherosclerosis and guide treatment decisions.

Conclusion

  • Ongoing education is crucial, with the understanding that guidelines and recommendations evolve as research progresses in the field of cardiovascular health.